Am J Transplant, Volume 19, Suppl 3 Archives - Page 145 of 214 - ATC Abstracts

2019 American Transplant Congress
A Cost Saving Quality Improvement Project in Solid Organ Transplant Population Following Tacrolimus Switch from Prograf® to Adoport® Immunosuppression – A Single Centre Experience
L. Mulreid, M. Vincent, L. Laycock, A. Summers, S. Bhutani
Manchester Royal Infirmary, Manchester, United Kingdom
*Purpose: Tacrolimus is widely used immunosuppressive drugs in transplantation. The use of generic medications is cost saving and economically advantageous for the National Health Services…
2019 American Transplant Congress
Development of an Aggressiveness Report Card
L. Liyanage, M. Kosztowski, S. Bae, K. Jackson, C. Holscher, A. Massie, N. Desai, M. Henderson, D. Segev, J. Garonzik-Wang
Johns Hopkins, Baltimore, MD
*Purpose: Use of suboptimal kidneys (SOKs) is not uniform across centers. We hypothesize that creating an aggressiveness report card (ARC) that provides surgeons with timely…
2019 American Transplant Congress
Impact of Granulocyte Colony Stimulating Factor on Clinical Outcomes in Kidney Transplant Recipients with Neutropenia
H. Yao¹, A. Alam², R. Sapir-Pichhadze², D. D’Arienzo³, D. Baran², S. Sandal², M. Cantarovich²
¹Critical Care Medicine, McGill University Health Center, Montreal, QC, Canada, ²Nephrology and Multi-Organ Transplant Program, McGill University Health Center, Montreal, QC, Canada, ³Medicine, McGill University Health Center, Montreal, QC, Canada
*Purpose: Neutropenia, defined as an absolute neutrophil count (ANC)
2019 American Transplant Congress
Adjunctive Therapy With Tocilizumab For Treatment Of Acute Antibody Mediated Rejection – 2 Year Experience
K. Venkatachalam, R. Delos Santos, B. Heady, A. Malone, T. Alhamad
Washington University, St. Louis, MO
*Purpose: Reporting our center's experience in use of tocilizumab for treatment of antibody mediated rejection*Methods: We have previously reported the efficacy of Tocilizumab (TCZ), an…
2019 American Transplant Congress
Hepatocellular Carcinoma in Fontan Liver Disease
V. Lamm¹, J. Wedd², C. Haydek², C. Obineme², A. Noll², H. Veeramachaneni², M. Muftah², R. Ford²
¹Internal Medicine, Emory, Atlanta, GA, ²Emory, Atlanta, GA
*Purpose: To add to the clinical characteristics and outcomes of hepatocellular carcinoma (HCC) in post Fontan operation patients and present, to the best of our…
2019 American Transplant Congress
Anti-CD272 Antibody (6B2) Induced Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allograft
E. Yin, M. Uchiyama, Y. Yamamoto, M. Niimi
Teikyo University, Tokyo, Japan
*Purpose: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA; CD272) has been implicated in the regulation of autoimmune and may potentially play an important…
2019 American Transplant Congress
IL-10+ Plasma Cells Are Not Required for Breg Activity and Are Counterbalanced by Novel Pro-Inflammatory Plasma Cells
Q. Ding, Y. Zhou, Z. Song, L. Zeng, D. Rothstein
University of Pittsburgh, Pittsburgh, PA
*Purpose: Classically, B cells differentiate into Ab-secreting plasma cells (PCs; B220lowCD138hiBlimp1+Ig+) providing humoral immunity. B cells can also inhibit or promote immune responses through the…
2019 American Transplant Congress
The C-Statistic Provides No Information on the Accuracy of Program Evaluations or the Presence of Unmeasured Confounders
A. Wey, N. Salkowski, B. Kasiske, M. Skeans, S. Gustafson, A. Israni, J. Snyder
SRTR, Minneapolis, MN
*Purpose: The C-statistic of risk-adjustment models is regularly used to assess accuracy of program evaluations or determine presence of unmeasured confounding. However, the C-statistic depends…
2019 American Transplant Congress
Lack of Linguistically and Culturally Tailored Initiatives in Kidney Transplant Programs in the United States
S. Carbunaru¹, A. Ortiz², C. Ortiz³, J. Ortiz³, J. Locke⁴, J. Caicedo¹
¹Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ²University of California, Los Angeles, Los Angeles, CA, ³Department of Surgery, University of Toledo College of Medicine & Life Sciences, Toledo, OH, ⁴University of Alabama at Birmingham, Birmingham, AL
*Purpose: Although minorities are the majorities in the kidney transplant waiting list, it is unknown if kidney transplant programs in United States have implemented linguistically…
2019 American Transplant Congress
A Financial Analysis of Elderly Kidney Transplant Recipients
A. Yaldo, I. Bajjoka, C. Crombez, M. Abouljoud
Henry Ford Transplant Institute, Detroit, MI
*Purpose: To compare and evaluate outcomes of for younger (Y) versus elderly (E) kidney transplant recipients (KTR) during the first year post-transplant. As the number…